A recently published study produced by an independent expert offers recommendations to assist the European Medicines Agency’s communication on the benefits and risks of medicines.

The report is a result of a year long project carried out by Dr Frederic Bouder and aims to provide evidence based input.

The study not only contains a detailed analysis of the expectations and attitudes of the different stakeholders of the agency regarding its communication on medicines but also draws up detailed recommendations for the agency such as the setting up of a risk communication advisory board.

The report further recommends the involvement of patients in communication activities, a review of the handling of its communication tools and to shape a strategic view on transparency.

The agency has already implemented some of the suggested recommendations.

Read the entire report here